Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial

Evotec Phase 1 Orthopoxvirus Antibody Trial

Analysis based on 7 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026

Sentiment
20
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement highlights Evotec's capabilities in biodefense and continuous biologics manufacturing, potentially strengthening its position for future government contracts. The news may positively influence investor sentiment for Evotec, though the financial impact is modest given the early-stage nature of the program.

Biotechnology Pharmaceuticals Defense

Evotec SE announced the initiation of a Phase 1 clinical trial for JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its subsidiary Evotec — Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program. The trial is a first-in-human study evaluating the prophylactic therapy intended to protect warfighters from biological threats such as smallpox and mpox. Manufacturing of clinical trial material was completed at the J.POD facility in Redmond, Washington, using continuous bioprocessing. This milestone fulfills the scope of a 2023 contract with the U.S. Department of War, which, together with an earlier 2022 plague antibody contract, has a combined potential value of up to $123.9 million. The program demonstrates the scalability of Evotec — Just – Evotec Biologics' continuous manufacturing platform for biodefense preparedness.

100 Evotec initiated Phase 1 trial
80 Evotec — Just – Evotec Biologics manufactured clinical trial material
stock
Evotec announced the Phase 1 trial initiation, showcasing its subsidiary's progress and potentially enhancing its reputation in biodefense, though no immediate revenue impact is expected.
Importance 100.0 Sentiment 20.0
subs
As the developer and manufacturer, Evotec — Just – Evotec Biologics achieved a key milestone, validating its continuous manufacturing platform and strengthening its portfolio of government contracts.
Importance 90.0 Sentiment 20.0
govactor
The Department of War is the funding and contracting entity, advancing its biodefense countermeasure program through this Phase 1 trial, supporting its mission to protect warfighters.
Importance 80.0 Sentiment 10.0
govactor
BARDA collaborated on the contract, contributing to the development of medical countermeasures, though its role is supportive and not directly impacted.
Importance 30.0 Sentiment 5.0
per
As EVP Global Head of Evotec — Just – Evotec Biologics, Zuckerman is a spokesperson for the program, with no direct financial impact.
Importance 20.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.